Phathom Pharmaceuticals, Inc. (PHAT) Institutional Ownership

Ownership Summary

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has 168 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors held 79.1% of outstanding shares in December 2025, down from 85.4% in September 2025.
• They decreased total shares held in Phathom Pharmaceuticals by -0.07% from last quarter, and the number of investors in PHAT increased 17.48% annually.
• Of these 168 holders, 96 added to their stakes in Phathom Pharmaceuticals, 50 trimmed positions, and 22 made no changes.
• Institutional investors collectively held 58.04Mn shares in Phathom Pharmaceuticals as of December 2025, down by 37.92K shares quarter on quarter, and down 10.65Mn shares year over year.
• As of December 31, 2025, the biggest holder of Phathom Pharmaceuticals is Frazier Life Sciences Management, L.P. at 12.47Mn shares, representing 16.99% of shares outstanding.
• Leading buyers of Phathom Pharmaceuticals shares for the quarter ending December 2025 were Divisadero Street Capital Management, LP (662.31K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (394.89K), NEXT CENTURY GROWTH INVESTORS LLC (393.77K), JANE STREET GROUP, LLC (277.51K), D. E. Shaw & Co., Inc. (261.07K).
• Top sellers of PHAT stock for the quarter ending December 2025 included MILLENNIUM MANAGEMENT LLC (3.0Mn), Catalio Capital Management, LP (429.52K), Ameriprise Financial Inc (368.85K), Bank Of America Corp /De/ (239.19K), WASATCH ADVISORS LP (205.55K).
• Per Business Quant, the top 10 investors in PHAT for the quarter ending December 2025 include Frazier Life Sciences Management, L.P. (12.47Mn), Medicxi Ventures Management (Jersey) Ltd (7.46Mn), Invesco Ltd. (3.92Mn), BlackRock, Inc. (3.56Mn), Carlyle Group Inc. (3.5Mn), VANGUARD GROUP INC (3.18Mn), MILLENNIUM MANAGEMENT LLC (2.08Mn), NEA Management Company, LLC (1.96Mn), 683 Capital Management, LLC (1.78Mn), WASATCH ADVISORS LP (1.33Mn).